Author: Newsdesk

Posted on

Mineral Resources and Mineral Reserves 2020

PR Newswire

BOLIDEN, Sweden, Feb. 12, 2021 /PRNewswire/ —

The Mineral Resources and Mineral Reserves situation in Aitik, Garpenberg and Kevitsa is stable. During the year, exploration continued to be successful at the Tara Deep mineralization and Mineral Resources in the Boliden Area increased as a result of exploration at the Rävliden deposit.

– “We have a stable situation in our major mines, and developments are advancing in Tara and the Boliden Area. Naturally, the fact that we’ve begun underground drilling in Tara is very good news,” says Stefan Romedahl, President, Business Area Mines.

The cost of exploration in 2020 was SEK 504 m (570). Some exploration activities were affected by restrictions related to Covid-19.

Aitik

No large-scale exploration is currently in progress in Aitik, however, mining preparation work is continuing with the Liikavaara deposit, around 3 km northwest of Aitik. Exploration and evaluation is also in progress at the Nautanen deposit, around 15 km north of Aitik. Mineral Reserves in Aitik, including Liikavaara, increased by 165 Mtonnes (14%) while Mineral Resources fell by 210 Mtonnes (19%). Design changes and a refined cost model have allowed the Mineral Resource to be converted to a Mineral Reserve. 42 Mtonnes were milled during 2020. New estimations of resources in Nautanen during 2020 showed an increase of 5.7 Mtonnes (36%).

The Boliden Area

In the Boliden Area, exploration at the Rävliden mineralization in Kristineberg continued. Drilling, test mining and metallurgical testing were carried out during 2020 and a new Mineral Resource estimation has shown an increase in the Mineral Resource by 2.7 Mtonnes. The Mineral Reserve increased in Renström but fell in Kristineberg and Kankberg. In all, the Mineral Reserves fell by 1.2 Mtonnes (9%), which is less than milled during the year (1.6 Mtonnes). The Mineral Resource increased by 2.7 Mtonnes (12%).

Garpenberg

Garpenberg has good advance planning with Mineral Resources and Reserves. Exploration and studies were successful during the year and the Mineral Reserve increased by 14.7 Mtonnes (20%). In Garpenberg, 3.0 Mtonnes were milled during 2020. Exploration in Garpenberg has contributed as much as was mined in 2020, but by promoting such large tonnages to Mineral Reserves, Mineral Resources have been reduced by 6.4 Mtonnes (9%).

Kevitsa

In Kevitsa, the Mineral Reserve decreased by 12 Mtonnes (9%), 9.5 Mtonnes of which was mined during the year. Design changes, including wider ramps and higher cut-offs for the next two years, have caused the remainder of the reduction. Conversely, the Mineral Resource increased by 22 Mtonnes (14%). New borehole information and a new geological model are the most important factors behind this increase.

Tara

Exploration at the Tara Deep mineralization continued with drilling from the surface, while drifting is underway toward Tara Deep at a depth of around 1000 meters. Drifting has progressed far enough that drilling toward Tara Deep has begun from underground. Drilling from the surface has been successful and Tara Deep is now estimated to include 26 Mtonnes of inferred Mineral Resources, compared with 22 Mtonnes in 2019, which has also contributed to an increase in Tara’s total Mineral Resource of 4.7 Mtonnes (16%). Meanwhile, work on improving the geological models of the mineralization and designing stopes in the Tara mine continues. Together with the contribution from drilling, this has resulted in the replacement of the entire year’s mining output of 2.3 Mtonnes and an increase in the Mineral Reserve of 700 Ktonnes (4%).

Calculation of Mineral Resources and Mineral Reserves, 2020

Boliden follows the recommendations of the Swedish Mining Association (SveMin) for reporting exploration results, Mineral Reserves and Mineral Resources and strives to report according to the Pan-European Reserves and Resources Reporting Committee (PERC). The PERC standard has clearer requirements for documentation and the competent persons who must evaluate the information that companies report. The transition to the PERC standard is a process that takes place during a transitional period until the company has had time to switch to using the PERC standard. As far as possible, this review is carried out in compliance with the PERC standard, but the reporting does not claim to be completely in accordance with the regulatory framework. All summarizing reports for Mineral Resources and Mineral Reserves per project and mine are reviewed and approved by competent persons presented in the relevant report. This summary of Mineral Resources and Mineral Reserves has been reviewed and approved by Gunnar Agmalm, Competent Person and Head of Ore Reserves and Project Evaluation, Boliden, which is a member of The Australasian Institute of Mining and Metallurgy (AusIMM) and The Fennoscandian Association for Metals and Minerals Professionals (FAMMP), both of which are approved organizations for competent persons according to PERC.

 


Planning prices                                  

                                   


Long-term prices 2020  

                                   


Change compared to 2019                                           

                                   

Zinc  

                                   

USD 2,400/metric ton  

                                   

Copper  

                                   

USD 6,600/metric ton  

                                   

Nickel  

                                   

USD 16,000/metric ton  

                                   

Lead  

                                   

USD 2,100/metric ton  

                                   

Gold  

                                   

USD 1,300/tr. oz  

 

 

+100

                                   

Silver  

                                   

USD 17/tr. oz  

                                   

Palladium  

                                   

USD 1,200/tr. oz  

 

 

+200

                                   

Platinum  

                                   

USD 1,000/tr. oz  

                                   

Cobalt  

                                   

USD 20/lb  

                                   

Tellurium  

                                   

USD 30/kg  

                                   

Molybdenum  

                                   

USD 8/lb  

                                   

USD/SEK  

 

8.0

                                   

EUR/SEK  

 

9.35

                                   

EUR/USD  

 

1.17

   

This information is information that Boliden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Director Communications, at 07.49 CET on February 12, 2020.

For further information, please contact:
Klas Nilsson, Director Group Communications, phone: +46 70-453 65 88

Boliden is a metals company with a focus on sustainable development. Our roots are Nordic, our market global. Our core competence lies within the fields of exploration, mining, smelting and metal recycling. Boliden has more than 5,700 employees and an annual turnover of SEK 50 billion. The share is listed in the Large Cap segment on NASDAQ OMX Stockholm 



www.boliden.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/boliden/r/mineral-resources-and-mineral-reserves-2020,c3285713

The following files are available for download:


https://mb.cision.com/Main/997/3285713/1372123.pdf

Appendix Mineral resources and mineral reserves 2020 (PDF)


https://mb.cision.com/Public/997/3285713/bbe50e6298ee4c0d.pdf

Press release (PDF)

 

Cision View original content:http://www.prnewswire.com/news-releases/mineral-resources-and-mineral-reserves-2020-301227481.html

SOURCE Boliden

Posted on

Biotage AB (publ) Year-End report January – December 2020

Double-digit organic growth

PR Newswire

UPPSALA, Sweden, Feb. 12, 2021 /PRNewswire/ — October – December

  • Net sales amounted to 298.1 MSEK (288.6), an increase by 3.3 percent, and organically* an increase by 10.0 percent.
  • Operating profit amounted to 59.6 MSEK (37.9).
  • The operating margin amounted to 20.0 percent (13.1).
  • Result after tax amounted to 44.4 MSEK (18.5).
  • Earnings per share was 0.68 SEK (0.28) before and after dilution.
  • The cash flow from operating activities increased to 87.5 MSEK (76.3).
  • Net cash* at December 31 was 157.0 MSEK (net debt -69.2).
  • Cash and cash equivalents amounted to 371.3 MSEK (185.9).
  • Liabilities to credit institutions amounted to 110.0 MSEK (109.6).
  • On November 4 the Board of Directors announced that a decision was taken to not convene an Extraordinary General Meeting to decide on dividends due to the continued uncertainty concerning the effects of the Corona pandemic.

January – December

  • Net sales amounted to 1,092.3 MSEK (1,101.4), a decrease by 0.8 percent, and organically* an increase by 1.4 percent.
  • Operating profit amounted 206.2 MSEK (208.1).
  • The operating margin amounted to 18.9 percent (18.9).
  • Result after tax amounted to 175.31) MSEK (186.8).
  • Earnings per share was 2.691)SEK (2.87) before and after dilution.
  • The cash flow from operating activities amounted to 279.0 MSEK (211.8).
  • On August 18 the Board of Directors decided to carry out a new share issue and to repurchase 243,313 class C shares in accordance with the resolution of the Annual General Meeting.
  • On August 31 it was announced that the total number of shares increased by 243,313, corresponding to 24,331.3 votes after the new issue of class C shares, and that the shares had been repurchased.
  • The Board of Directors intends to propose to the Annual General Meeting a dividend to the shareholders for 2020 of 1.50 SEK (0) per share, corresponding to 55.8 percent of the result after tax. According to the dividend policy Biotage shall distribute at least 50 percent of the net profit.

Comments by the CEO 

Double-digit organic growth -a record quarter

It is with immense pride that I present this report on the last quarter and the full year 2020, especially under the challenging conditions caused by the ongoing Corona pandemic (COVID-19).

I note with satisfaction that we after the second and third quarters, that were greatly affected by the pandemic, now once again deliver a strong quarter. In fact, our sales are the highest ever in a single quarter, for the full year this means continued organic growth for the Group. For the fourth quarter the reported sales were 3.3 percent higher compared to the corresponding period 2019, which organically was a 10.0 percent increase. For the full year the corresponding figures were a decrease by 0.8 percent and an organic growth by 1.4 percent.

The operating margin, EBIT, improved by 6.9 percentage points in the quarter compared to last year and achieved a margin of 20.0 percent.

For the full year the EBIT margin amounted to 18.9 percent, the same as last year.

It was our largest single product area, Organic chemistry, that contributed the most to the success in the fourth quarter, as its share of our sales increased by no less than 7 percentage points, from 46 to 53 percent, and 51 percent for the full year. All geographical areas except Japan showed growth for these products in the fourth quarter. The Asian countries had the strongest development, but it is also worth noting that the US came back strongly with a double-digit percentage sales increase and a record for the quarter.

Biotage’s Scale-up product area saw a sales decrease, which was due to a reduction of CBD sales in the US. Instead, we focused resources and activities on parties active in vaccine manufacturing. This contributed to increased sales and some recovery for Scale-up, which we see as very positive. We have long striven to broaden our customer and application base for the area and we have now further strengthened this work.

Many of our customers in the Analytical chemistry product area are among those who have been hit hard by the consequences of the pandemic. This applies in particular to commercial laboratories working with the analysis of patient samples. Here, however, we saw a gradual increase in activity levels during the quarter, which hopefully may indicate a trend break.

Another effect of the covid-19 pandemic was that Biotage’s sales and beta testing in the Biomolecules product area was limited as we had fewer opportunities to visit customers. A commercial launch of our automated plasmid purification system at maxi, mega and giga scale is approaching and is planned for the first half of 2021.

Our product mix continued to have an overweight of system sales in the quarter, accounting for 51 percent. Great sales successes for our purification systems in all regions except Japan contributed to this.

Geographically we continue to build a stronger presence in Asia. China and South Korea remain double-digit growth markets for Biotage. We also see great potential in India which, however, was hard struck by the restrictions resulting from the pandemic. Fortunately, we still noted a strong recovery of the operations in India in the latter part of the year. In Japan sales did not meet our expectations, but also here we saw positive signs with increased sales in the last quarter. After two quarters with weaker figures, the Americas ended the year with recovery in the last quarter, and I am very delighted to see that EMEA showed growth both in the quarter and the full year.

Looking at important investments during the year, we have expanded the machinery with automation solutions at our production unit in Cardiff, UK to strengthen manufacturing capacity. This work will continue in 2021. Furthermore, we have started work on the completion of a completely new building in Cardiff. It will be used primarily for the production of various types of consumables, with improved and more efficient production flows. We expect the first part of the expansion to be completed in the summer of 2021.

We are investing in efficiencies also in our production of the PhyTip® consumables in the Biomolecules product area in the US. In 2020 we started a project to introduce automation solutions that are currently undergoing production tests. We expect to be able to deploy them in the spring of 2021.

For our future development it is reassuring to see our strong balance sheet with a net cash of 157.0 MSEK, which is a 226.2 MSEK improvement compared to last year’s net debt of 69.2 MSEK. Through focused work we have improved our operating capital by 9.2 MSEK compared to the last full year.

The year has certainly been very challenging for us all, professionally as well as on the private level. For many the Covid-19 pandemic has blurred the boundary between home and workplace. This has been and continues to be a challenge in terms of work environment issues and the balance between work and leisure. Throughout this period, Biotage has constantly been working to maintain a high level of information to the Group’s employees, both on the global level and as country specific instructions in the various regions. We have utilized digital meetings and tried to facilitate homework for all employees by providing mobile computers, screens, office chairs, etc.

It is our assessment that we will continue to live with the limitations of the pandemic also in 2021. Through the lessons we take with us from this time, we are likely to work differently also when the pandemic is finally over. During the pandemic we have learned to work with greater flexibility. We have also travelled less both within and across national borders, which contributes to diminishing our environmental footprint and to increasing sustainability. We have developed new methods of working and been forced to be innovative and swift in order to overcome various problems.

Finally, I would like to take this opportunity to thank all our talented employees who, despite very challenging external circumstances, have enabled the Group to continue to perform at such a high level. Biotage is well positioned and I am very much looking forward to continuing with another successful year 2021.

Uppsala February 12 2021 

Tomas Blomquist

President and CEO

Calendar

Interim report January – March 2021

April 28 2021

Annual General Meeting 2021

April 28 2021

The Annual Report for 2020 is planned to be published

Week 14 2021

Interim Report January – June 2021

July 16 2021

Interim report January – September 2021

October 28 2021

Year-end report 2021

February 11 2022

All financial reports are published at www.biotage.com

The interim report for Biotage AB (publ) has been issued by the Company’s President and CEO Tomas Blomquist after authorization by the Board of Directors.

Uppsala February 12, 2021
Tomas Blomquist
President and CEO

For further information:

Tomas Blomquist, President and CEO
phone: +46 705 23 01 63                                                                                                                    

Annette Colin, CFO
phone: +46 703 19 06 76       

This information is information that Biotage AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, on February 12, 2021 at 08:00 CET.

Biotage in brief

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1.092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage’s share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.

Website: www.biotage.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/biotage/r/biotage-ab–publ–year-end-report-january—december-2020,c3285484

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/biotage-ab-publ-year-end-report-january—december-2020-301227480.html

SOURCE Biotage

Posted on

New 10K/15K Resolution Line Scan Image Sensors from ams Enable Higher Throughput in Optical Inspection Systems

New 10K/15K Resolution Line Scan Image Sensors from ams Enable Higher Throughput in Optical Inspection Systems

News facts:

  • 4LS line scan image sensors operate at speeds up to 120,000 lines per second
  • Independent lines of RGB + Clear sensor channels support full-color reproduction; digital TDI capability for excellent image quality in dim light
  • 4LS supports rigorous quality and process controls in next-generation smart factories

PREMSTAETTEN, Austria–(BUSINESS WIRE)–
ams (SIX: AMS), a leading worldwide supplier of high-performance sensor solutions, today launches the 4LS series, adding new faster and higher resolution line scan image sensors to its broad family of sensors for machine-vision applications. Use of cameras equipped with 4LS sensors will help operators of the latest smart factories to maintain the highest standards of quality control while increasing the volume of production output.

Offered in versions with 10K and 15K resolutions, the 4LS image sensors feature four Red/Green/Blue/Clear channels scanning at up to 120,000 lines per second. The 4LS series offers the system designer flexibility to meet various application requirements. Each of the four lines may be independently controlled and operated simultaneously for full-color image capture. Camera manufacturers can also implement 4:1 digital TDI (Time Delay and Integration) to achieve high image quality in low lighting conditions, or to perform high-speed object inspection. In addition, the sensors offer the choice of either an 8-bit or 12-bit LVDS output to provide the most appropriate trade-off between image quality and speed. Full well-charge options range from 10 ke- to 40 ke- to enable use in a wide range of illumination conditions.

The introduction of new faster, higher-resolution line scan image sensors creates a new opportunity for industrial-camera manufacturers and machine-vision system developers to add value to their products by enabling higher throughput and more effective optical inspection in applications such as: print inspection; continuous-surface and web inspection; food sorting and quality control; display inspection; and glass inspection.

Peter Vandersteegen, Segment Marketing Manager at ams, said: “ams has built a strong market position and an enviable reputation in the field of line scan image cameras with ams Dragster sensors. Now the launch of the 4LS image sensors provides designers of line scan image cameras a new option to increase scanning speeds and to support improved full-color image reproduction.”

ams delivering 1D/2D/3D technologies for machine vision

Machine vision encompasses a wide range of applications in factory automation, Automatic Identification and Data Capture (AIDC), volume and distance measurement, motion analysis, intelligent transportation systems, and document scanning. In addition to the Dragster and new 4LS line scanning sensor products, ams offers several product families addressing an ongoing need for various machine-vision applications and use cases in 1D/2D/3D. A more recent application is the vision of the environment for ever more complex autonomous robots and cobots.

“ams is a leader for VCSEL-based illuminators and high quantum efficiency NIR image sensors,” says Pierre Laboisse, Executive Vice President Global Sales and Marketing, ams. “This equipment benefits from accurate 2D, and ideally 3D visualizations of the environment and object to be worked with. Near infrared illumination, both with flood- and high-contrast dot illuminators, combined with sensitive NIR image sensors enables compact, cost effective, and high-performance 3D systems immune to uncontrolled illumination conditions.”

Compatible interface for family of camera products

The 4LS line scan image sensor is supplied as a Chip-on-Board (CoB) module mounted on a mechanically robust and thermally stable Invar package. The PCB interfaces of the 4LS 10K and 4LS 15K are fully compatible and interchangeable, allowing line scan camera manufacturers to build a family of products with different resolutions.

Pixel size in the new 4LS line scan image sensors is 5.6µm x 5.6µm. Dynamic range is up to 54dB, and quantum efficiency is 61% at 530nm.

ams continues to supply the Dragster series of line scan image sensors, which are available in single-line and two-line versions, and with resolution ranging from 2K to 16K.

The four-line 4LS line scan sensors are in volume production and are available for ordering via ams authorized distribution partners. For more technical information or for sample requests, go to https://ams.com/4LS.

Amy Flécher

Vice President Marketing Communications / ams AG

[email protected]

ams.com

KEYWORDS: Austria Europe

INDUSTRY KEYWORDS: Technology Photography Manufacturing Audio/Video Software Other Manufacturing

MEDIA:

Logo
Logo
Posted on

Boliden’s fourth quarter: Strong earnings and cash flow for the quarter

PR Newswire

BOLIDEN, Sweden, Feb. 12, 2021 /PRNewswire/ — Revenues for the fourth quarter amounted to SEK 16,170 m (12,972) and operating profit, excluding revaluation of process inventory, totaled SEK 3,043 m (1,721). Free cash flow totaled SEK 2,750 m (822). For the full year, revenues amounted to SEK 56,321 m (49,936) and operating profit, excluding revaluation of process inventory, totaled SEK 8,438 m (7,035).

“A very good quarter. At our mines, development in Kevitsa is particularly positive, while production at the smelters has been characterized by a high level of stability,” says Mikael Staffas, President and CEO.

The operating profit in Business Area Mines increased to SEK 1,858 m (890), mainly due to higher grades and overall good production. The milled volume in Kevitsa increased by more than 30% compared to the fourth quarter of 2019 and in Garpenberg 3.0 Mtonnes were milled in 2020, which is in line with the current environmental permit. Aitik’s milled volume was in line with the previous year, but has not yet reached the new design capacity. The Boliden Area’s earnings were positively affected by a good ore mix with a high proportion of gold, while production in Tara was affected by maintenance and some disruptions. The Kylylahti mine was closed down during the quarter, and the mine is now being prepared for reclamation and the concentrator is being mothballed.

Within Business Area Smelters, operating profit, excluding revaluation of process inventory, increased to SEK 1,109 m (759) as a result of higher volumes. In Rönnskär, production of most metals increased compared to the corresponding period last year due to good process stability and new capacity. In Harjavalta, copper production was also higher than in the fourth quarter of 2019 after completed investments, while production of nickel in matte was slightly lower. Zinc production in both Kokkola and Odda was characterized by high stability and was higher than in the previous year. Production in Bergsöe was lower than the corresponding period last year due to poorer supply and lower quality of input materials.

At the start of 2021, Boliden submitted an application for membership in the International Council on Metals and Mining (ICMM). The aim of membership is to work with other member companies to develop the industry’s work on various aspects of sustainability.

For further information, please contact:

Klas Nilsson, Director Group Communications, tel.: +46 70 453 65 88

Boliden is a metals company with a focus on sustainable development. Our roots are Nordic, our market global. Our core competence lies within the fields of exploration, mining, smelting and metal recycling. Boliden has around 6,000 employees and an annual turnover of SEK 50 billion. The share is listed in the Large Cap segment on NASDAQ OMX Stockholm.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/boliden/r/boliden-s-fourth-quarter–strong-earnings-and-cash-flow-for-the-quarter,c3285702

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/bolidens-fourth-quarter-strong-earnings-and-cash-flow-for-the-quarter-301227478.html

SOURCE Boliden

Posted on

Boliden: Q4 Interim Report and Year-end report for 2020

PR Newswire

BOLIDEN, Sweden, Feb. 12, 2021 /PRNewswire/ —

 Q4 2020

  • Revenues totaled SEK 16,170 m (12,972) 
  • The operating profit totaled SEK 3,077 m (1,744)
  • The operating profit, excluding the revaluation of process inventory, totaled SEK 3,043 m (1,721)
  • Free cash flow totaled SEK 2,750 m (822)
  • Earnings per share totaled SEK 8.60 (4.97)

Strong earnings and cash flow during the quarter 

  • Stable production in Mines and Smelters.
  • The Board of Directors proposes a payment to the shareholders of SEK 14.25 per share through:
    • oan ordinary dividend of SEK 8.25 (7.00) per share.
    • oan extra payment of SEK  6.00 (0.00) per share through automatic share redemption.

Please find enclosed the full report.

The Interim Report will be presented via a webcast/conference call on Friday, 12 February at 09:30 (CET). Information is available at www.boliden.com.


Contact persons for information:

Mikael Staffas, President & CEO  

Tel: +46 8 610 15 00

Håkan Gabrielsson, CFO   

Tel: +46 8 610 15 00

Olof Grenmark, Director Investor Relations

Tel: +46 70 291 57 80

This information is information that Boliden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Director Investor Relations, at 07.45 CET on 12 February, 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/boliden/r/q4-interim-report-and-year-end-report-for-2020,c3285703

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/boliden-q4-interim-report-and-year-end-report-for-2020-301227476.html

SOURCE Boliden

Posted on

Palito Near-Mine Exploration Success

For immediate release

            12 February 2021

Serabi Gold plc

(“Serabi” or the “Company”)

Palito Near-Mine Exploration Success

Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to announce further positive results from its ongoing regional exploration activity at its Calico target, which is located just 5km from the Palito Operation and Processing plant.  In addition, initial regional soil geochemistry on the Sao Chico/Sao Domingos trend has recorded multiple significant gold and multi-element anomalies within this highly prospective mineralised corridor.

A PDF version of this release including all images can be accessed using the following link

https://bit.ly/2Z9WGat

Highlights

  • Identification of significant geochemical gold-in-soil anomalies at Calico, Juca and Forquilha, of which Calico is now very significant over a two kilometre by two kilometre area.  Values as high as 0.8g/t gold have been recorded, better than have been seen in any soils over the Palito orebody.
  • Subsequent terrestrial geophysics survey using Induced Polarisation (“IP”) covering the Calico soil anomaly has identified multiple chargeability anomalies. 
  • Both results are very comparable in terms of scale and signature to the Palito orebody, a 600,000 ounce resource, being mined today.
  • First pass drill-testing of the Calico prospect is planned in the coming months.
  • Multi-element soil anomalies confirm strike extension of known gold occurrences at the Fofoca prospect on the Sao Chico/ Sao Domingos trend. 

             

             

Mike Hodgson CEO commented:

“These positive results from the regional programmes at Calico and Fofoca are very encouraging.  After the interruptions to the exploration campaign of 2020 due to the pandemic, this year we are embarking on the most substantial exploration effort seen by Serabi to date.  Whilst a key focus will be targeting resource growth at the existing Palito and Sao Chico orebodies, a significant part of the exploration programme is more regionally focussed whilst still within 20 kilometres of these producing orebodies.  Both Calico and Fofoca fall into this category. 

“At Calico the results to date are very compelling and, even at this early stage, lead us to start drawing positive comparisons with the Palito orebody.  The Calico location was first observed as a significant electromagnetic anomaly from the airborne survey completed in 2018.  In the Tapajos, such electromagnetic highs are typically indicators of sulphide bodies, which, as we see at Palito and Sao Chico and elsewhere, can often be gold-bearing.

“Calico is located just five kilometres from Palito, and in the past months we have completed follow-up terrestrial geophysical and geochemical surveys.  The soil geochemistry programme defined several highly interesting anomalies, namely Calico, Juca and Forquilha, of which Calico is the most significant.  Measuring two kilometres by two kilometres and with soil assays as high as 0.8g/t, this anomaly is comparable to the geochemical anomaly over the Palito orebody.  This geochemical survey has now been complemented by IP which has proven to be very effective at Palito.  The IP has highlighted a series of NW-SE anomalies, some sited within the bounding gold soil anomaly at depth and some adjacent to the soil anomalies.  The orientation of these IP anomalies is consistent with broader regional structural fabric and the trend of the veins at Palito, just five kilometres away.  Given its proximity to Palito and the fact that it shares many similar characteristics including what seems to be a similar geochemical and geophysical signature, we plan to conduct some initial first pass drilling during the coming months.

“The geochemical survey at Fofoca, located in the eastern part of the Sao Domingos tenement acquired by the Company in late 2020, is still in progress.  The initial results have defined a number of new geochemical anomalies outside the multiple past and present artisanal mining areas.  The survey will continue with a follow-up drill programme to be undertaken once this is completed.”

            Figure 1 – Regional Exploration at Palito Complex, showing Palito and Sao Chico, and the Calico and Fofoca prospects.


To access this image please use the following link



https://bit.ly/3rMAlvR

             
            Figure 2 – Detailed Image of the Calico/Forquilha/Juca area showing local geology as well as multiple gold and copper geochemical anomalies


To access this image please use the following link



https://bit.ly/3rFWbkQ

             
            Figure 3 – Detailed image of Calico showing local Geology, Gold and Copper Geochemistry as well as terrestrial geophysics – IP anomalies


To access this image please use the following link



https://bit.ly/2Z6eu6r

RESULTS

The Calico prospect and neighbouring Forquila and Juca prospects were initially identified from the interpretation of an airborne electromagnetic survey completed in 2018.  These areas were initially selected where multiple electromagnetic anomalies (typically indicators of massive sulphides in the Tapajos), coincided with an ESE-WNW trending regional structure, known as Mato Cobra, a structure displaying strong magnetic and radiometric anomalism. 

Reconnaissance field mapping identified alteration (potassic, haematitic and silicic) and evidence of weathered and primary sulphides in limited outcrop associated with felsic intrusive and volcanic rocks.

Systematic grid soil sampling subsequently identified a number of cohesive multi-element geochemical anomalies of which the most significant was the Calico prospect.

The Calico prospect is highlighted by a central potassically altered dacite porphyry intrusive with coincident higher temperature soil geochemistry multi-element signature of Mo-Bi-As-Te-W-Sn.  This dacite porphyry intruding into a monzogranite was bounded by a broad 2km by 2km high gold/low antimony halo to the NW and anomalous copper wrapping around the southern part of the intrusive core.

The 50 metre by 200 metre grid soil sampling defined a broadly arcuate shaped two kilometre by two kilometre gold in soil anomaly defined by 1,532 soil samples, with a maximum of 0.8g/t Au, with 260 samples reporting analytical results between 0.03g/t and 0.8g/t Au.  This gold anomaly is supported by a suite of multi-elements suggesting an intrusion related mineralising system (porphyry or intrusion related gold system model).

In 2020 Serabi completed a 44.5 line kilometre IP survey covering the gold in soil anomaly at Calico. The survey was completed on 200 metre spaced, north south orientated traverses, with an array designed to penetrate to at least 250 metres vertical depth.

The result of this survey has further refined the interpretation of the Calico prospect.  The IP highlighted a series of NW-SE anomalies, as seen at Palito.  These IP anomalies bound the gold soil anomaly and are adjacent to the dacite porphyry intrusive. Between these structures a series of transverse (NE-SW) and NNW-SSE structures (second and third order faults) have been identified which correlate with the peaks of the gold in soil assays.

With favourable geological mapping, coincidental IP anomalies and gold geochemical anomalies, the Company will be focussing on first pass drill testing of these targets in the coming months. 

This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

The person who arranged for the release of this announcement on behalf of the Company was Clive Line, Director.

Enquiries:

Serabi Gold plc  
Michael Hodgson Tel: +44 (0)20 7246 6830
Chief Executive Mobile: +44 (0)7799 473621
   
Clive Line Tel: +44 (0)20 7246 6830
Finance Director Mobile: +44 (0)7710 151692
   
Email: [email protected]  
Website:  www.serabigold.com  
   
Beaumont Cornish Limited
Nominated Adviser and Financial Adviser		  
Roland Cornish Tel: +44 (0)20 7628 3396
Michael Cornish Tel: +44 (0)20 7628 3396
   
Peel Hunt LLP
UK Broker		  
Ross Allister Tel: +44 (0)20 7418 8900
   
   

Copies of this announcement are available from the Company’s website at www.serabigold.com.

Neither the Toronto Stock Exchange, nor any other securities regulatory authority, has approved or disapproved of the contents of this announcement.

GLOSSARY OF TERMS

The following is a glossary of technical terms:

“Ag” means silver.
“Au” means gold.
“assay” in economic geology, means to analyse the proportions of metal in a rock or overburden sample; to test an ore or mineral for composition, purity, weight or other properties of commercial interest.
“CIM” means the Canadian Institute of Mining, Metallurgy and Petroleum.
“chalcopyrite” is a sulphide of copper and iron.
“Cu” means copper.
“cut-off grade” the lowest grade of mineralised material that qualifies as ore in a given deposit; rock of the lowest assay included in an ore estimate.
“dacite porphyry intrusive” a silica-rich igneous rock with larger phenocrysts (crystals) within a fine-grained matrix
“deposit” is a mineralised body which has been physically delineated by sufficient drilling, trenching, and/or underground work, and found to contain a sufficient average grade of metal or metals to warrant further exploration and/or development expenditures; such a deposit does not qualify as a commercially mineable ore body or as containing ore reserves, until final legal, technical, and economic factors have been resolved.
“electromagnetics” is a geophysical technique tool measuring the magnetic field generated by subjecting the sub-surface to electrical currents.
“garimpo” is a local artisanal mining operation
“garimpeiro” is a local artisanal miner.
“geochemical” refers to geological information using measurements derived from chemical analysis.
“geophysical” refers to geological information using measurements derived from the use of magnetic and electrical readings.
“geophysical techniques” include the exploration of an area by exploiting differences in physical properties of different rock types. Geophysical methods include seismic, magnetic, gravity, induced polarisation and other techniques; geophysical surveys can be undertaken from the ground or from the air.
“gossan” is an iron-bearing weathered product that overlies a sulphide deposit.
“grade” is the concentration of mineral within the host rock typically quoted as grams per tonne (g/t), parts per million (ppm) or parts per billion (ppb).
“g/t” means grams per tonne.
“granodiorite” is an igneous intrusive rock similar to granite.
“hectare” or a “ha” is a unit of measurement equal to 10,000 square metres.
“igneous” is a rock that has solidified from molten material or magma.
“IP” refers to induced polarisation, a geophysical technique whereby an electric current is induced into the sub-surface and the conductivity of the sub-surface is recorded.
“intrusive” is a body of rock that invades older rocks.
“mineralisation” the concentration of metals and their chemical compounds within a body of rock.
“mineralised” refers to rock which contains minerals e.g. iron, copper, gold.
“Mo-Bi-As-Te-W-Sn” Molybdenum-Bismuth-Arsenic-Tellurium-Tungsten-Tin
“monzogranite” a biotite rich granite, often part of the later-stage emplacement of a larger granite body.
“mt” means million tonnes.
“ore” means a metal or mineral or a combination of these of sufficient value as to quality and quantity to enable it to be mined at a profit.
“oxides” are near surface bed-rock which has been weathered and oxidised by long term exposure to the effects of water and air.
“ppm” means parts per million.
“saprolite” is a weathered or decomposed clay-rich rock.
“sulphide” refers to minerals consisting of a chemical combination of sulphur with a metal.
“vein” is a generic term to describe an occurrence of mineralised rock within an area of non-mineralised rock.
“VTEM” refers to versa time domain electromagnetic, a particular variant of time-domain electromagnetic geophysical survey to prospect for conductive bodies below surface.

Assay Results

The assay results reported within this release are those provided by the Company’s own on-site laboratory facilities at Palito and have not been independently verified.  Serabi closely monitors the performance of its own facility against results from independent laboratory analysis for quality control purpose.  As a matter of normal practice the Company sends duplicate samples derived from a variety of the Company’s activities to accredited laboratory facilities for independent verification. Based on the results of this work, the Company’s management are satisfied that the Company’s own facility shows good correlation with independent laboratory facilities. The Company would expect that in the preparation of any future independent Reserve/Resource statement undertaken in compliance with a recognised standard, the independent authors of such a statement would not use Palito assay results but only use assay results reported by an appropriately certificated laboratory.

Qualified Persons Statement

The scientific and technical information contained within this announcement has been reviewed and approved by Michael Hodgson, a Director of the Company. Mr Hodgson is an Economic Geologist by training with over 26 years’ experience in the mining industry. He holds a BSc (Hons) Geology, University of London, a MSc Mining Geology, University of Leicester and is a Fellow of the Institute of Materials, Minerals and Mining and a Chartered Engineer of the Engineering Council of UK, recognising him as both a Qualified Person for the purposes of Canadian National Instrument 43-101 and by the AIM Guidance Note on Mining and Oil & Gas Companies dated June 2009.

Forward Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ‘‘believe’’, ‘‘could’’, “should” ‘‘envisage’’, ‘‘estimate’’, ‘‘intend’’, ‘‘may’’, ‘‘plan’’, ‘‘will’’ or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors. A number of factors could cause actual results to differ materially from the results discussed in the forward looking statements including risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors, many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements.

ENDS

 

Attachment



Posted on

Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis

Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis

  • Second country to authorize trial initiation after recent UK MHRA approval, further country approvals pending
  • Trial enrollment expected to begin during the first half of 2021

PARIS–(BUSINESS WIRE)–
Regulatory News:

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LYS-GM101, the company’s gene therapy candidate for the treatment of GM1 gangliosidosis, a serious, pediatric, life threatening disease. LYS-GM101 builds on Lysogene’s extensive experience in direct to CNS adeno-associated viral vector (AAV)-based gene therapy clinical development.

The IND clearance follows the recent clinical trial authorization granted by the MHRA in the United Kingdom. Lysogene intends to initiate its global, multi-center, single-arm, two-stage, adaptive-design clinical trial of LYS-GM101 in patients with a diagnosis of early or late infantile GM1 gangliosidosis. The clinical trial will include a safety phase and a confirmatory efficacy phase. The company intends to dose a total of 16 patients, with dosage of the first patient expected in the first half of 2021.

“We are very pleased to receive this IND clearance for LYS-GM101 which completes the MHRA approval received a few weeks ago. It represents a major milestone that marks our second CNS gene-therapy program to enter into a global clinical trial” said Karen Aiach, Founder Chairman and Chief Executive Officer of Lysogene.“This IND clearance once again demonstrates our quality and timely execution, and our strong determination to bring new therapeutic solutions for diseases that currently have no treatment.”

Christine Waggoner, President and Co-Founder of Cure GM1 Foundation added: “Children with GM1 gangliosidosis represent a clear unmet medical need and we are thrilled to see a new therapeutic option entering the clinic, as it brings tremendous hope to families and the entire GM1 gangliosidosis community.”

LYS-GM101 (‘adeno-associated viral vector serotype rh.10 expressing beta-galactosidase’) received orphan drug designation for the treatment of GM1 gangliosidosis in the European Union and in the US in 2017, as well as Rare Pediatric Disease designation in the US in 2016.

Leading international gene therapy and Lysosomal Storage Disease centers plan to participate in the clinical trial (NCT04273269).

Lysogene is also funding a GM1 gangliosidosis natural history study being conducted by Casimir Trials to collect prospective and/or retrospective videos of children doing certain everyday tasks and behaviors in infantile and juvenile GM1 gangliosidosis (NCT04310163).

About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptative clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Forward Looking Statement

This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Stéphane Durant des Aulnois

Chief Financial Officer

[email protected]

+ 33 1 41 43 03 99

KEYWORDS: Europe United States North America France

INDUSTRY KEYWORDS: Health FDA Genetics Other Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Altran Collaborates With Ciena’s Blue Planet Division to Address Virtualization and Orchestration Needs for 5G

Co-created solutions will accelerate market opportunities by simplifying and automating service delivery across multiple vendor systems

NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) — Altran, part of Capgemini, and Blue Planet, a division of Ciena, today announced a collaboration to provide network operators with intelligent automation solutions. This collaboration will support operators that are grappling with increasingly complex requirements across physical and virtual domains driven by 5G, cloud and the Internet of Things (IoT). As a result of their co-created solutions, service delivery across multiple vendor systems will be simplified and automated, enabling operators to monetize their investments faster.

Intelligent automation is the execution of the operational and functional processes involved in designing, creating and delivering an end-to-end service. Traditionally, these processes were handled by domain-specific, siloed operational support systems (OSS) and tools built for static environments. The increasing integration of advanced networking technologies and automation has accelerated demand for process orchestration – a market projected to exceed $9 billion by 2025, according to Market Study Report LLP.

Through the collaboration, Blue Planet and Altran intend to pursue opportunities in service orchestration, cloud orchestration, inventory, analytics, network assurance, OSS/BSS integration and network automation. Blue Planet’s Intelligent Automation Portfolio is a comprehensive, open software suite that empowers service providers with deep insights about the network to optimize business processes, reduce costs and improve the customer experience. Blue Planet is purpose-built for closed-loop automation combining multi-domain service orchestration, inventory federation, with analytics and assurance, unlocking network potential and business agility. As part of the Capgemini Group, Altran will provide its specialized offerings in the areas of system integration, engineering and R&D services, deployment, managed and support services. This combined with its unique, leading-edge software frameworks will be integrated with Blue Planet’s portfolio.

“Altran’s collaboration with Blue Planet enables operators to seize new service opportunities as they transform their existing infrastructure into next-generation networks that employ software-defined networking and network functions virtualization,” said Dietmar Wendt, Chief Global Sales & Portfolio Officer, Engineering and R&D at Capgemini. “Our co-created solutions will help operators shorten time to revenue by simplifying and automating service delivery across multiple vendor ecosystems and equipment that span the WAN, data center and cloud.”

Rick Hamilton, Senior Vice President of Blue Planet, a division of Ciena, said, “Our partnership with Altran is key to executing digital transformation initiatives for operators around the globe looking to transform networks and realize the full potential of a software-defined and open approach.”

Altran has worked with Ciena for many years, providing design engineering and product services and support. For more on Altran’s specialized offerings, please visit www.altran.com.

To arrange a media interview with an Altran expert, please contact Chevaan Seresinhe at + 44 7971 967644 or [email protected].

For more on Blue Planet’s portfolio, please visit www.blueplanet.com.

About Altran

Altran is an integral part of Capgemini, a global leader in consulting, digital transformation, technology and engineering services. The Group is at the forefront of innovation to address the entire breadth of clients’ opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year + heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. Capgemini is driven by the conviction that the business value of technology comes from and through people. Today, it is a multicultural company of 270,000 team members in almost 50 countries. With Altran, the Group reported 2019 combined revenues of €17billion. People matter, results count.

Visit us at altran.com.

Altran

Chevaan Seresinhe
[email protected]
Tel: + 44 7971 967644



Posted on

YAMAHA MOTOR: Consolidated Business Results Summary — Fiscal Year 2020 Ending December 31 —

YAMAHA MOTOR: Consolidated Business Results Summary — Fiscal Year 2020 Ending December 31 —

IWATA, Japan–(BUSINESS WIRE)–
Yamaha Motor Co., Ltd. (TOKYO:7272) announces consolidated business results for the full fiscal year. Net sales were 1,471.3 billion yen (a decrease of 193.5 billion yen, or 11.6% compared with the previous fiscal year). Operating income was 81.7 billion yen (a decrease of 33.7 billion yen, or 29.2%), ordinary income was 87.7 billion yen (a decrease of 31.8 billion yen, or 26.6%), and net income attributable to owners of parent was 53.1 billion yen (a decrease of 22.7 billion yen, or 29.9%) . We were able to partly recover from the negative effects of the COVID-19 pandemic in the first half with net sales results in the fourth quarter (October -December) at 404.2 billion yen (an increase of 6.7 billion yen, or 1.7% on the same period over the previous fiscal year), and operating income was 25.3 billion yen (an increase of 9.9 billion yen, or 64.5%). For the fiscal year, the U.S. dollar was traded at 107 yen (an appreciation of 2 yen against the previous fiscal year), and the euro at 122 yen (no change from the previous term).

For net sales, although sales increases in the Robotics and Financial Services Businesses were achieved, the Motorcycles and Marine Products Businesses within the Land Mobility Business saw decreases in sales volumes due to the effects from the COVID-19 pandemic, which resulted in a decline in sales overall. Operating income declined overall due to factors such as the impact of foreign exchange rates and decreases in operation rates due to the temporary closures of factory operations in each country.

Forecast of Consolidated Business Results for the next fiscal year ending December 31, 2021

Net Sales

:

1,700.0 billion yen

Operating Income

:

110.0 billion yen

Ordinary Income

:

110.0 billion yen

Net Income Attributable to Owners of Parent

:

72.0 billion yen

About Yamaha Motor Co., Ltd.

Yamaha Motor (TOKYO: 7272) is a world-leading enterprise manufacturing land-mobility such as motorcycles, all-terrain vehicles, and electrically power assisted bicycles, marine products such as boats and outboard motors, robotics products such as surface mounters and drones, as well as engagement in the finance business. The company’s diverse businesses and wide variety of products are built around its proprietary technologies focused on powertrain, chassis and hull, electronic control, and manufacturing technologies. Yamaha Motor operates global development, production and sales networks through 140 subsidiaries and equity-method affiliates in 30 countries and regions, working to realize our Corporate Mission of being a “Kando* Creating Company.” About 90% of consolidated net sales are generated in more than 180 countries and regions outside of Japan. Please visit http://global.yamaha-motor.com.

Naoto Horie

Corporate Communication Division

Global PR Team

Yamaha Motor Co., Ltd.

TEL: +81(0)3-5220-7211

[email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Automotive Manufacturing Automotive Technology Manufacturing Maritime Transport Other Automotive Other Manufacturing Motorcycles Engineering Hardware

MEDIA:

Logo
Logo
Posted on

Tetragon Financial Group Limited Investor Call on 26 February 2021

PR Newswire

LONDON, Feb. 12, 2021 /PRNewswire/ — Tetragon will host a conference call for investors on Friday, 26 February 2021 at 15:00 GMT / 10:00 EST to discuss its annual report and to provide a company update.

During the call, Tetragon’s investment manager will also seek to address questions raised by investors, including questions e-mailed to [email protected].

Getting Access to the Call and Q&A:

The audio conference call may be accessed by dialling +44 (0) 800 358 9473 in the United Kingdom and +1 855 857 0686 in the United States. Please be prepared to provide the Participant Pin Code 99853880#.

The call will be accompanied by a live presentation which can be viewed online by registering at the link below. In addition, questions can be submitted online while watching the presentation. You will still need to dial in to the audio portion of the call above if you choose to view the presentation online. We would encourage you to log in 15 minutes prior to the start of the call.

https://onlinexperiences.com/Launch/QReg/ShowUUID=E3AB3AD4-C41B-4404-BD25-4D040363ADFA

Presentation Replay:

A replay of the call will be available for 30 days through the link provided above or by visiting http://www.tetragoninv.com/investors/calendar-and-events where a recording will be posted.

About Tetragon:

Tetragon is a closed-ended investment company that invests in a broad range of assets, including public and private equities and credit (including distressed securities and structured credit), convertible bonds, real estate, venture capital, infrastructure, bank loans and TFG Asset Management, a diversified alternative asset management business. Where appropriate, through TFG Asset Management, Tetragon seeks to own all, or a portion, of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon’s investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit, equity, interest rate, inflation and real estate cycles. The company is traded on Euronext in Amsterdam N.V. and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company’s website at www.tetragoninv.com.


Tetragon:

 

Yuko Thomas

Investor Relations


[email protected]


Press Inquiries:

 

Prosek Partners



[email protected]

United States

Andy Merrill and Ryan Fitzgibbon

+1 212 279 3115 ext. 216 and ext. 234

United Kingdom

Harriet Sloane

+44 (0) 7771 810 803

This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Financial Markets Supervision Act as a collective investment scheme from a designated country.

Cision View original content:http://www.prnewswire.com/news-releases/tetragon-financial-group-limited-investor-call-on-26-february-2021-301227169.html

SOURCE Tetragon Financial Group Limited